Table 3 Clinical trial experience with mTOR inhibitors in lymphoma

Everolimus [38]

Phase II, single-arm, monotherapy (10 mg/day PO)

MCL (n = 19)

DLBCL (n = 47)

Follicular grade 3 (n = 8)

Other lymphomas (n = 3)

MCL 32%

DLBCL 30%

Follicular grade III 38%

Other lymphomas 0%

Everolimus [39]

Phase I/II single-arm, monotherapy (5 or 10 mg/day PO)

MCL (n = 4)

Other hematologic malignancies (n = 23)

MCL 0%

Other 4%

Temsirolimus [40]

Phase II, single-arm, monotherapy (250 mg IV weekly)

MCL (N = 34)

38%

Temsirolimus [41]

Phase II, single-arm, monotherapy (25 mg IV weekly)

MCL (N = 27)

41%

Temsirolimus [42]

Phase III, monotherapy (175 mg IV weekly for 3 weeks, then 25 mg [n = 54] or 75 mg IV weekly [n = 54]) vs investigator-chosen chemotherapy (n = 54)

MCL (N = 162)

Temsirolimus 25 mg 6%

Temsirolimus 75 mg 22%

Investigator-chosen 2%

Ridaforolimus [43]

Phase II, single-arm, monotherapy (12.5 mg/day IV on days 1-5 every 2 weeks)

MCL (n = 9)

Other hematologic malignancies (n = 43)

MCL 33%

Others 5%

Waldenström macroglobulinemia

Everolimus [44]

Phase II, single-arm, monotherapy (10 mg/day)

WM (N = 50)

42% (PR)

Hodgkin lymphoma

Everolimus [45]

Phase II, single-arm, monotherapy (10 mg/day)

HL (N = 19)

HL 47%

GVHD

Sirolimus [46]

Retrospective chart review, sirolimus conditioning (12 mg loading dose days 1-3, then 4 mg daily) vs standard conditioning

GVHD prophylaxis after HSCT for lymphoma (N = 126)^a

Overall survival:

Sirolimus 66%

Standard conditioning 38%